Incannex Healthcare (IXHL) Stock: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$3.21
-0.04 (-1.23%)
▼
5d:
-3.31%
30d:
-1.83%
90d:
-19.55%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $3.21, which is considered oversold relative to its 30-day fair value range of $3.21 to $3.59. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.3) compared to its historical average (3.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IXHL is in a uptrend. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.97 (+459.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IXHL is in a uptrend. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.97 (+459.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.21 -
$3.59
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 459.8% below Wall St target ($17.97)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.21 -
$3.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.13
Resistance Level
$3.72
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$17.97
(+459.8%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-1.3 vs 3.7
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 11:51 PM ET
Data refreshes hourly during market hours. Next update: 12:51 AM
Data refreshes hourly during market hours. Next update: 12:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
